275 related articles for article (PubMed ID: 35585651)
1. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.
Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG
J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764
[TBL] [Abstract][Full Text] [Related]
3. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
5. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
[TBL] [Abstract][Full Text] [Related]
6. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
7. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
8. A peptide derived from the N-terminus of charged multivesicular body protein 6 (CHMP6) promotes the secretion of gene editing proteins via small extracellular vesicle production.
Fan J; Pan J; Zhang X; Chen Y; Zeng Y; Huang L; Ma D; Chen Z; Wu G; Fan W
Bioengineered; 2022 Mar; 13(3):4702-4716. PubMed ID: 35188876
[TBL] [Abstract][Full Text] [Related]
9.
Ye Y; Shi Q; Yang T; Xie F; Zhang X; Xu B; Fang J; Chen J; Zhang Y; Li J
Technol Cancer Res Treat; 2022; 21():15330338221085370. PubMed ID: 35315725
[No Abstract] [Full Text] [Related]
10. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
[TBL] [Abstract][Full Text] [Related]
11. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
Yan B; Liang Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
[TBL] [Abstract][Full Text] [Related]
12. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
14. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
15. Quantification of protein cargo loading into engineered extracellular vesicles at single-vesicle and single-molecule resolution.
Silva AM; Lázaro-Ibáñez E; Gunnarsson A; Dhande A; Daaboul G; Peacock B; Osteikoetxea X; Salmond N; Friis KP; Shatnyeva O; Dekker N
J Extracell Vesicles; 2021 Aug; 10(10):e12130. PubMed ID: 34377376
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Chadwick AC; Musunuru K
Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
[TBL] [Abstract][Full Text] [Related]
17. TOP-EVs: Technology of Protein delivery through Extracellular Vesicles is a versatile platform for intracellular protein delivery.
Ilahibaks NF; Ardisasmita AI; Xie S; Gunnarsson A; Brealey J; Vader P; de Jong OG; de Jager S; Dekker N; Peacock B; Schiffelers RM; Sluijter JPG; Lei Z
J Control Release; 2023 Mar; 355():579-592. PubMed ID: 36746337
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
Horodecka K; Düchler M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
[TBL] [Abstract][Full Text] [Related]
19. Efficient SSA-mediated precise genome editing using CRISPR/Cas9.
Li X; Bai Y; Cheng X; Kalds PGT; Sun B; Wu Y; Lv H; Xu K; Zhang Z
FEBS J; 2018 Sep; 285(18):3362-3375. PubMed ID: 30085411
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]